entrectinib

{
  "id": "MLC-T-ONC-002860",
  "term": "entrectinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used in adults to treat non-small cell lung cancer that has spread and is ROS1 positive and in adults and children aged 1 month and older to treat certain types of solid tumors that have an NTRK gene fusion. It is also being studied in the treatment of other types of cancer. Entrectinib blocks certain proteins involved in cell signaling and cell growth. Blocking these proteins may help keep cancer cells from growing and may kill them. Entrectinib is a type of tyrosine kinase inhibitor. Also called Rozlytrek.",
    "An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types."
  ],
  "synonyms": [
    "Rozlytrek"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/entrectinib/"
}